secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023217
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics completes FX-322 Phase 2b enrollment; Q3 net loss $19.5M, cash $99.3M
--------------------------------------------------------------------------------

- Phase 2b study of FX-322 for SNHL enrolled 142 participants; primary endpoint readout expected Q1 2023.
- Second hearing restoration program FX-345 to begin Phase 1b in coming weeks; H2 2023 results expected.
- MS remyelination program advanced to IND-enabling studies; IND filing planned for H2 2023.
- Q3 2022 net loss $19.5M vs $25.2M in Q3 2021; R&D expenses $11.7M, down from $15.7M.
- Cash, equivalents and marketable securities $99.3M; expected to fund operations into 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/0000950170-22-023217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/freq-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer